Advocates of ultrasound contrast have launched a grassroots lobbying effort to persuade the U.S. Food and Drug Administration (FDA) to relax its recent black box warning on the use of two echocardiography contrast agents. The group believes the FDA warning was unnecessarily strident given the safety profile of ultrasound contrast, and that the warning could hamstring further clinical use of cardiac ultrasound contrast.
9